{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:26:27Z","timestamp":1790684787948,"version":"4.1.0"},"reference-count":30,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Ovarian cancer is one of the most common cancers of the reproductive organs. As there are no symptoms in the early stages, it is mainly detected in the advanced stages. Even then, the symptoms are non-specific and include, for example, abdominal pain, early satiety, or changes in bowel habits. Both biochemical marker levels and imaging studies are used in the initial diagnosis. However, it should be emphasized that they are not characterized by high specificity. Treatment is multistage, and usually first-line debulking surgery is used followed by platinum-based chemotherapy. Here we present a clinical case of a 56-year-old female, a carrier of a mutation in the BRCA1 gene, with a history of breast cancer and with recurrent epithelial ovarian cancer. The patient was qualified for treatment with a PARP inhibitor and is currently undergoing treatment with olaparib. In the patient\u2019s follow up of 50 months to date, there has been no recurrence of cancer. Few side effects have been observed, and the most serious one that can be effectively treated is anemia. On the basis of the described case, the authors concluded that olaparib treatment is effective, relatively safe, and does not significantly affect daily functioning.<\/jats:p>","DOI":"10.3390\/ijerph18073430","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T06:59:42Z","timestamp":1616741982000},"page":"3430","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Follow-Up of a Female Patient Treated with Olaparib\u2014Hope for a Long Life without Relapse?"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1176-2153","authenticated-orcid":false,"given":"Mateusz","family":"Koz\u0142owski","sequence":"first","affiliation":[{"name":"Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3133-2123","authenticated-orcid":false,"given":"Katarzyna","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Cymbaluk-P\u0142oska","sequence":"additional","affiliation":[{"name":"Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"ref_1","unstructured":"Ferlay, J. (2020). Global Cancer Observatory: Cancer Today, International Agency for Research on Cancer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian Cancer: An Integrated Review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.amepre.2015.09.023","article-title":"A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer","volume":"50","author":"Ebell","year":"2016","journal-title":"Am. J. Prev. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e22624","DOI":"10.1002\/jcla.22624","article-title":"Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer","volume":"33","author":"Kim","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-019-0503-7","article-title":"Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review","volume":"12","author":"Dochez","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14737140.2017.1299575","article-title":"Epidemiology and treatment patterns of epithelial ovarian cancer","volume":"17","author":"Jessmon","year":"2017","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.semcancer.2017.04.009","article-title":"Ovarian cancer stem cells more questions than answers","volume":"44","author":"Ottevanger","year":"2017","journal-title":"Semin. Cancer Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.critrevonc.2019.08.002","article-title":"Hopes and failures in front-line ovarian cancer therapy","volume":"143","author":"Tsibulak","year":"2019","journal-title":"Crit. Rev. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40259-019-00347-4","article-title":"PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review","volume":"33","author":"Cook","year":"2019","journal-title":"BioDrugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/1574892813666180305165256","article-title":"PARP Inhibitors in Ovarian Cancer","volume":"13","author":"Mittica","year":"2018","journal-title":"Recent Patents Anti Cancer Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ijgc-2018-000016","article-title":"Ovarian cancer: Screening and future directions","volume":"29","author":"Gupta","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs","year":"1990","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Arch. Pathol. Anat. Physiol. Klin. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: Evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA A Cancer J. Clin."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3802\/jgo.2015.26.2.87","article-title":"FIGO\u2019s staging classification for cancer of the ovary, fallopian tube, and peritoneum: Abridged republication","volume":"26","author":"Prat","year":"2015","journal-title":"J. Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Clinical Trials in Recurrent Ovarian Cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.15557\/CGO.2017.0001","article-title":"Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer","volume":"15","author":"Basta","year":"2017","journal-title":"Curr. Gynecol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1200\/JCO.2017.35.15_suppl.5520","article-title":"Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer","volume":"35","author":"Lim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/AOG.0000000000002580","article-title":"Ovarian Cancer Prevention and Screening","volume":"131","author":"Menon","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bpobgyn.2016.10.017","article-title":"Hereditary Ovarian Cancer and Risk Reduction","volume":"41","author":"Andrews","year":"2017","journal-title":"Best Pr. Res. Clin. Obstet. Gynaecol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.7150\/jca.30410","article-title":"BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance","volume":"10","author":"Gorodetska","year":"2019","journal-title":"J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","year":"2018","journal-title":"DNA Repair"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"43653","DOI":"10.18632\/oncotarget.17613","article-title":"Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting","volume":"8","author":"Dougherty","year":"2017","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Aledermann","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_29","unstructured":"Food and Drug Administration (2018, December 26). FDA Approved Olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP) for the Mainte-Nance Treatment of Adult Patients with Deleterious or Suspected Deleterious Germline or Somatic BRCA-Mutated (gBRCAm or sBRCAm) Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are in Complete or Partial Response to First-Line Platinum-Based, Available online: https:\/\/www.fda.gov\/drugs\/fda-approved-olaparib-lynparza-astrazeneca-pharmaceuticals-lp-maintenance-treatment-adult-patients."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/7\/3430\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:41:18Z","timestamp":1760161278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/7\/3430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["ijerph18073430"],"URL":"https:\/\/doi.org\/10.3390\/ijerph18073430","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]}}}